（文章来源：证券日报） 证券日报网讯 12月18日晚间，特宝生物发布公告称，公司2025年第一次临时股东大会审议通过《关于 取消监事会、修订的议案》《关于修订及制定公司部分治理制度的议案》。 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-048 厦门特宝生物工程股份有限公司 关于非独立董事辞任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 厦门特宝生物工程股份有限公司（以下简称"公司"）董事会于 2025 年 12 月 18 日收到非独立董事赖力平女士的书面辞任报告，因公司治理结构调 整，赖力平女士申请辞去第九届董事会非独立董事职务。除辞任非独立董事职 务外，赖力平女士在公司担任的其他职务不变。 公司于 2025 年 12 月 18 日召开职工代表大会并做出决议，选举赖力平 女士为第九届董事会职工代表董事，任期自本次职工代表大会审议通过之日起 至第九届董事会任期届满之日止。 一、董事离任情况 （一）提前离任的基本情况 | 姓名 | 离任 | | | 原定任期 | | | 是否继续在 上市公司及 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

上海市锦天城（深圳）律师事务所 关于 厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会之 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会之 法律意见书 致：厦门特宝生物工程股份有限公司 根据厦门特宝生物工程股份有限公司（以下简称"贵公司"或者"公司"） 的委托，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等法律、行政法规以及《厦 门特宝生物工程股份有限公司章程》（以下简称"《公司章程》"）、《厦门特 宝生物工程股份有限公司股东大会议事规则》（以下简称"《股东大会议事规 则》"）的规定，上海市锦天城（深圳）律师事务所（以下简称"本所"）指派 律师见证公司 2025 年第一次临时股东大会（以下简称"本次股东大会"），现 就公司本次股东大会召开的有关事宜出具本法律意见书。 本所同意将本法律意见书随贵 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-047 厦门特宝生物工程股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 本次会议由公司董事会召集，董事长孙黎先生主持。会议采用现场投票和网 络投票相结合的表决方式。本次股东大会的召集、召开程序及表决程序符合《公 司法》《证券法》及《公司章程》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 表决情况： 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 12 月 18 日 （二） 股东大会召开的地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 113,690,214 ...

格隆汇12月18日丨特宝生物(688278.SH)公布，公司董事会于2025年12月18日收到非独立董事赖力平女 士的书面辞任报告，因公司治理结构调整，赖力平女士申请辞去第九届董事会非独立董事职务。除辞任 非独立董事职务外，赖力平女士在公司担任的其他职务不变。 ...

两融数据显示，该股最新融资余额为13.95亿元，近5日减少3339.46万元，降幅为2.34%。 特宝生物12月17日大宗交易平台出现一笔成交，成交量3.24万股，成交金额270.67万元，大宗交易成交 价为83.54元。该笔交易的买方营业部为国泰海通证券股份有限公司总部，卖方营业部为广发证券股份 有限公司厦门湖滨南路证券营业部。 进一步统计，近3个月内该股累计发生9笔大宗交易，合计成交金额为6873.58万元。 证券时报·数据宝统计显示，特宝生物今日收盘价为83.54元，上涨0.29%，日换手率为0.31%，成交额为 1.06亿元，全天主力资金净流出848.53万元，近5日该股累计平盘报收，近5日资金合计净流出7451.72万 元。 据天眼查APP显示，厦门特宝生物工程股份有限公司成立于1996年08月07日，注册资本40818.948万人 民币。（数据宝） 12月17日特宝生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会 会议资料 （688278） 中国·厦门 厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会会议资料 会议须知 为保障厦门特宝生物工程股份有限公司（以下简称"公司"）全体股东 的合法权益，维护股东大会的正常秩序，确保本次股东大会顺利召开，根据 《公司章程》《股东大会议事规则》及有关法律法规的规定，特制定本须知， 望出席股东大会的全体人员遵照执行。 一、本公司董事会办公室具体负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东 代理人的合法权益，除出席会议的股东及股东代理人、公司董事、监事、高 级管理人员、公司聘请的律师及董事会邀请的人员外，公司有权依法拒绝其 他人员进入会场。 三、为保障本次股东大会的顺利召开，股东及股东代理人须在会议召 开前 30 分钟到会议现场办理签到手续，并按规定出示证券账户卡、身份证 明文件或企业营业执照/注册证书复印件（加盖公章）、授权委托书等，经 验证后方可出席会议。 四、本次股东大会采取现场投票和网络投票相结合的方式表决，结合 现场投票和网络投票的表决结果发布股东大会决议 ...